■来自长期输血和饮食摄入的过量铁会增加β-地中海贫血主要患者心脏并发症的风险。对于有铁超负荷风险的地中海贫血患者,通常使用去铁酮和地拉罗司。本研究旨在比较去铁酮和地拉罗司在β-地中海贫血主要患者中的表现和毒性。
■对102例重型β-地中海贫血患者进行了横断面观察。血清铁蛋白与总铁蛋白一起,间接,测量直接胆红素水平。肝酶水平,转氨酶(ALT),和天冬氨酸转氨酶(AST),也决心。铁蛋白与血清ALT的相关性,AST,根据Spearman等级相关法构建总胆红素。分析了去铁酮和地拉罗司组之间基于血清参数的统计学差异。还分析了接受短期(≤7年)和长期(>7年)输血者之间铁螯合剂作用的差异。
■胆红素的平均水平,ALT,AST,发现铁蛋白很高。铁蛋白与ALT(r=0.508,p<0.001)和AST(r=0.569;p<0.001)呈正相关。去铁酮和地拉罗司组之间的铁蛋白水平没有统计学差异(p=0.776)。然而,地拉罗司组的总胆红素和ALT高于去铁酮组(分别为p=0.001和0.022).总计(p<0.001),间接(p<0.001),长期输血患者的直接胆红素水平(p=0.015)明显高于短期输血患者。在长期输血组中发现较高的铁蛋白,统计学意义为p=0.008。
■铁蛋白在输血依赖性β-地中海贫血患者中含量较高,与ALT和AST呈正相关。与去铁酮相比,去拉罗司可能会造成更高的肝损伤风险。然而,在接受短期和长期输血的患者中,地拉罗司的疗效(基于铁蛋白水平)没有显著变化.
UNASSIGNED: Excess iron deriving from a chronic transfusion and dietary intake increases the risk for cardiac complications in β-thalassemia major patients. Deferiprone and
deferasirox are commonly prescribed to thalassemic patients who are at risk of iron overload. This study aimed to compare the performance and toxicity of deferiprone and
deferasirox in β-thalassemia major patients.
UNASSIGNED: A cross-sectional observation was performed on 102 patients with β-thalassemia major. Serum ferritin along with total, indirect, and direct bilirubin levels were measured. Levels of liver enzymes, transaminase (ALT), and aspartate transaminase (AST), were also determined. Ferritin correlations with serum ALT, AST, and total bilirubin were constructed based on Spearman\'s rank correlation. Statistical differences based on the serum parameters were analyzed between deferiprone and
deferasirox groups. The differences of iron chelators\' effects between those receiving short-term (≤7 years) and long-term (>7 years) blood transfusion were also analyzed.
UNASSIGNED: The averaged levels of bilirubin, ALT, AST, and ferritin were found to be high. Ferritin was positively correlated with ALT (r=0.508 and p<0.001) and AST ((r=0.569; p<0.001). There was no statistical difference in ferritin levels between the deferiprone and
deferasirox groups ( p=0.776). However, higher total bilirubin and ALT were observed in the deferasirox group than in the deferiprone group ( p=0.001 and 0.022, respectively). Total ( p<0.001), indirect ( p<0.001), and direct bilirubin levels ( p=0.015) were significantly higher in patients with long-term transfusions than those receiving short-term transfusions. Higher ferritin was found with a statistical significance of p=0.008 in the long-term transfusions group.
UNASSIGNED: Ferritin is high in people with transfusion-dependent β-thalassemia major and positively correlated with ALT and AST.
Deferasirox might pose a higher risk of developing hepatic injury as compared with deferiprone. Yet, no significant change of deferasirox efficacy (based on ferritin level) was found between those receiving short-term and long-term transfusions.